Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363(21): 1981-5.
Marek RJ, Ben-Porath YS, Ashton K, Heinberg LJ. Impact of using DSM-5 criteria for diagnosing binge eating disorder in bariatric surgery candidates: Change in prevalence rate, demographic characteristics, and scores on the Minnesota Multiphasic Personality Inventory-2 restructured form (MMPI-2-RF). Int J Eat Disord 2014; 47(5): 553-7.
Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, et al. The effectiveness of opioid substitution treatments for patients with opioid dependence: A systematic review and multiple treatment comparison protocol. Syst Rev 2014; 3: 105.
Firestone Cruz M, Fischer B, Patra J, Kalousek K, Newton-Taylor B, Rehm J, et al. Prevalence and associated factors of hepatitis C infection (HCV) in a multi-site Canadian population of illicit opioid and other drug users (OPICAN). Can J Public Health 2007; 98(2): 130-3.
Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54(1): 71-80.
Hall W, Bell J, Carless J. Crime and drug use among applicants for methadone maintenance. Drug & Alcohol Dependence 1993; 31(2): 123-9.
Bawor M, Dennis BB, Bhalerao A, Plater C, Worster A, Varenbut M, et al. Sex differences in outcomes of methadone maintenance treatment for opioid use disorder: A systematic review and meta-analysis. CMAJ Open 2015; 3(3): E344-E351.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; (3): CD002209.
Isbell H, Vogel VH. The addiction liability of methadon (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome. Am J Psychiatry 1949; 105(12): 909-14.
Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Nguyen QC, et al. Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Qual Life Res 2012; 21(4): 613-23.
Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA 1998; 280(22): 1936-43.
Caplehorn JR, Lumley TS, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend 1998; 52(1): 57-61.
Strike CJ, Gnam W, Urbanoski K, Fischer B, Marsh DC, Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict Behav 2005; 30(5): 1025-8.
Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11(2): 193-206.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. Int J Drug Policy 2011; 22(2): 167-71.
Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: Prevalence estimates and risk factors. Int J Drug Policy 2015; 26(2): 183-90.
Bachireddy C, Bazazi AR, Kavasery R, Govindasamy S, Kamarulzaman A, Altice FL. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: Implications for secondary prevention. Drug Alcohol Depend 2011; 116(1-3): 151-7.
Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, et al. Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49(9): 1433-40.
Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J, et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110(4): 646-55.
Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction 2008; 103(11): 1828-36.
Hosztafi S, Furst Z. Therapy in heroin addiction. Neuropsychopharmacol Hung 2014; 16(3): 127-40.
Wei X, Wang L, Wang X, Li J, Li H, Jia W. A study of 6-year retention in methadone maintenance treatment among opioid-dependent patients in Xi'an. J Addict Med 2013; 7(5): 342-8.
Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study. Lancet Psychiatry 2015; 2(10): 901-8.
Van Nguyen H, Nguyen HL, Mai HT, Le HQ, Tran BX, Hoang CD, et al. Stigmatization among methadone maintenance treatment patients in mountainous areas in northern Vietnam. Harm Reduct J 2017; 14(1): 1.
Socias ME, Wood E, Small W, Dong H, Shoveller J, Kerr T, et al. Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use. Drug Alcohol Depend 2016; 168: 211-8.
Zhou K, Li H, Wei X, Li X, Zhuang G. Medication adherence in patients undergoing methadone maintenance treatment in Xi'an, China. J Addict Med 2017; 11(1): 28-33.
Ledberg A. Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013. J Subst Abuse Treat 2017; 74: 35-41.
Ratcliffe K, Chopra B, Day E. Understanding diversion of prescribed opioid agonist medications in Birmingham, UK-prevalence and predictors of diversion. Heroin Addict Relat Clin Probl 2017; 27-40.
Keegan D, Crowley D, Laird E, Van Hout MC. Prevalence and risk factors for Hepatitis C viral infection amongst a cohort of Irish drug users attending a drug treatment centre for Agonist Opioid Treatment (AOT). Heroin Addict Relat Clin Probl 2017; 19(1): 45-55.
Peles E, Sason A, Schreiber S, Adelson M. Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: A national contingency management approach trial. Am J Addict 2017; 26(2): 167-75.
Holland R, Maskrey V, Swift L, Notley C, Robinson A, Nagar J, et al. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial. Addiction 2014; 109(4): 596-607.
Jiao M, Gu J, Xu H, Hao C, Lau JT, Mo P, et al. Resilience associated with mental health problems among methadone maintenance treatment patients in Guangzhou, China. AIDS Care 2017; 29(5): 660-5.
Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, et al. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. J Psychoactive Drugs 2015; 47(2): 149-57.
Comiskey CM, Snel A. Using client's routine urinalysis records from multiple treatment systems to model five-year opioid substitution treatment outcomes. Subst Use Misuse 2016; 51(4): 498-507.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. Low-dose memantine attenuated methadone dose in opioid-dependent patients: A 12-week double-blind randomized controlled trial. Sci Rep 2015; 5: 10140.
Zhang X, Xu H, Gu J, Lau JT, Hao C, Zhao Y, et al. Depression, suicidal ideation, and related factors of methadone maintenance treatment users in Guangzhou, China. AIDS Care 2016; 28(7): 851-6.
Darker C, Sweeney B, El Hassan H, Kelly A, O' Connor S, Smyth B, et al. Non-attendance at counselling therapy in cocaine-using methadone-maintained patients: Lessons learnt from an abandoned randomised controlled trial. Ir J Med Sci 2012; 181(4): 483-9.
Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol 2007; 17(6-7): 377-93.
O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294(8): 961-3.
Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract 2009; 15(3): 227-34.
Liu J, Dilixiati Y, Li F, Zhang F, Mo L, Jiao L, et al. Cox regression analysis on maintenance duration and affecting factors of methadone maintenance treatment. Chin J AIDS STD 2007; 13(2): 160-1.
Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006; 82(3): 211-7.
Liang T, Liu EW, Zhong H, Wang B, Shen LM, Wu ZL. Factors influencing the rate on retention to methadone maintenance treatment program among heroin addicts in Guizhou, China. Zhonghua Liu Xing Bing Xue Za Zhi 2009; 30(2): 131-5.
Lin C, Wu Z, Rou K, Yin W, Wang C, Shoptaw S, et al. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat 2010; 38(2): 119-27.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. Methadone maintenance and cessation of injecting drug use: Results from the Amsterdam Cohort Study. Addiction 2000; 95(4):
Strang J, Tober G. Methadone matters: Evolving community methadone treatment of opiate addiction. Boca Raton, FL: CRC Press; 2003.
Simpson DD. The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry 1979; 136(11): 1449-53.
Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98(5): 673-84.